GenFleet Therapeutics (Shanghai) Inc.
勁方醫藥科技(上海)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT
PROPOSED SHARE REPURCHASE ON THE MARKET

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the "**Company**") on a voluntary basis to inform the shareholders (the "**Shareholders**") and potential investors of the Company about the latest developments of the Company.

Reference is made to the notice (the "**Notice**") of the annual general meeting (the "**AGM**") and the circular (the "**Circular**") of the Company dated April 17, 2026, as well as the announcement of the poll results of the AGM dated May 11, 2026. Pursuant to the resolution passed by the Shareholders at the AGM held on May 11, 2026, the board of directors of the Company (the "**Board**") was granted a general mandate (the "**Share Repurchase Mandate**") to repurchase H shares of the Company (the "**H Shares**"). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Notice and the Circular.

On June 29, 2026, the Board formally resolved to exercise the Share Repurchase Mandate and proposed to repurchase H Shares on the open market from time to time (the "**Share Repurchase**"), with a maximum amount not exceeding HK$350 million. The Share Repurchase will continue until the expiry of the Share Repurchase Mandate. The Company will conduct the Share Repurchase in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The Company will conduct the Share Repurchase in accordance with the Company's articles of association, the Listing Rules, the Hong Kong Codes on Takeovers and Mergers and Share Buy-backs, the Company Law of the People's Republic of China, and all applicable laws and regulations. The Company intends to finance the Share Repurchase with its own financial resources.

The Board considers that the current trading price of the Shares undervalues the intrinsic value and development prospects of the Company, and that the Share Repurchase will enhance shareholder value. The Share Repurchase reflects the Board's confidence in the long-term development of the Company and will only be carried out when the Board, as per continuous assessment of the Company's business prospects, financial condition, share price performance and market situation, considers it appropriate and in the best interest of the Company and its Shareholders as a whole.

Shareholders and potential investors should note that the Share Repurchase will be subject to market conditions and will be made at the sole discretion of the Board. There is no assurance as to the timing, quantity or price of any Share Repurchase. Therefore, Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, June 29, 2026

As at the date of this announcement, the Board of the Company comprises:(i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.